Table 2.
The relationship between different genotype and endoscopy/pathologic diagnoses.
| Genotype | PU | SC-NAG | Mi-IM | Mo-IM | S-IM | M-AG | |
|---|---|---|---|---|---|---|---|
| CLA | WT | 157 (36.8%) | 51 (11.9%) | 92 (21.5%) | 17 (4.0%) | 1 (0.2%) | 3 (0.7%) |
| Mutation | 43 (24.7%) | 12 (6.9%) | 41 (23.6%) | 13 (7.5%) | 1 (0.6%) | 1 (0.6%) | |
| Heteroresistance | 23 (23.5%) | 8 (8.2%) | 20 (20.4%) | 6 (6.1%) | 0 (0.0%) | 1 (1.0%) | |
| LEV | WT | 172 (38.0%) | 47 (10.4%) | 104 (23.0%) | 20 (4.4%) | 1 (0.2%) | 2 (0.4%) |
| Mutation | 29 (20.4%) | 15 (10.6%) | 26 (18.3%) | 9 (6.3%) | 1 (0.7%) | 2 (1.4%) | |
| Heteroresistance | 23 (23.2%) | 10 (10.1%) | 24 (24.2%) | 7 (7.1%) | 0 (0.0%) | 1 (1.0%) |
PU, peptic ulcer; SC-NAG, severe chronic non-atrophic gastritis; Mi-IM, mild intestinal metaplasia; Mo-IM, moderate intestinal metaplasia; S-IM, severe intestinal metaplasia; M-AG, mild atrophic gastritis; WT, wild type; CLA, clarithromycin; LEV, levofloxacin.